Grace Therapeutics, Inc. Common Stock (GRCE)

• Market cap: $40.6M
• 1 day: 6.95%
• 5 days: 9.89%
• 1 month: 21.21%
• 3 months: 23.46%
• 6 months: 23.46%
• Year to date: 23.46%
• 1 year: 23.46%
• 5 years: 23.46%
• 10 years: -98.35%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Employees: 4

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1% more capital invested

Capital invested by funds: $6.31M [Q2] → $6.36M (+$57.2K) [Q3]

0% more funds holding

Funds holding: 12 [Q2] → 12 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4